deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04268550

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8
Interventions Selpercatinib
Updated 14 times since 2020 Last updated: Jul 9, 2025 Started: Apr 8, 2020 Primary completion: Mar 1, 2026 Completion: Mar 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Recurrent Lung Non-Small Cell Carcinoma and Stage IV Lung Cancer AJCC v8 and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 14 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Dec 2020 · 7 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~May 2023 · 8 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jan 2024 · 7 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Aug 2025 · 8 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Dec 2024 — Aug 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 9 earlier versions

  1. Jan 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jun 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  3. May 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Dec 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

  6. Jan 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  7. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  8. May 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Mar 2020 — May 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • SWOG Cancer Research Network
Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Amarillo, United States , Ames, United States , Anaconda, United States , Anaheim, United States , Ann Arbor, United States , Antigo, United States , Asheboro, United States , Ashland, United States , Atlanta, United States and 238 more locations